Cargando…
Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?
Current treatment for inflammatory bowel disease (IBD) includes the application of anti-inflammatory agents for the induction and remission of IBD. However, prolonged use of anti-inflammatory agents can exert adverse effects on patients. Recently, formulated dietary approach in treating IBD patients...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100370/ https://www.ncbi.nlm.nih.gov/pubmed/33525858 http://dx.doi.org/10.5217/ir.2020.00035 |
_version_ | 1783688772944134144 |
---|---|
author | Shafiee, Nor Hamizah Manaf, Zahara Abdul Mokhtar, Norfilza M. Raja Ali, Raja Affendi |
author_facet | Shafiee, Nor Hamizah Manaf, Zahara Abdul Mokhtar, Norfilza M. Raja Ali, Raja Affendi |
author_sort | Shafiee, Nor Hamizah |
collection | PubMed |
description | Current treatment for inflammatory bowel disease (IBD) includes the application of anti-inflammatory agents for the induction and remission of IBD. However, prolonged use of anti-inflammatory agents can exert adverse effects on patients. Recently, formulated dietary approach in treating IBD patients is utilized to improve clinical activity scores. An alteration of gastrointestinal microbiota through dietary therapy was found to reduce IBD and is recognized as a promising therapeutic strategy for IBD. One of the recommended formulated diets is an anti-inflammatory diet (AID) that restricts the intake of carbohydrates with modified fatty acids. This diet also contains probiotics and prebiotics that can promote balanced intestinal microbiota composition. However, scientific evidences are limited to support this specific dietary regime in maintaining the remission and prevention relapse of IBD. Therefore, this review aimed to summarize available data from various studies to evaluate the AID diet effectiveness which will be useful for clinicians to manage their IBD patients by application of improved dietary therapy. |
format | Online Article Text |
id | pubmed-8100370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Association for the Study of Intestinal Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-81003702021-05-14 Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? Shafiee, Nor Hamizah Manaf, Zahara Abdul Mokhtar, Norfilza M. Raja Ali, Raja Affendi Intest Res Review Current treatment for inflammatory bowel disease (IBD) includes the application of anti-inflammatory agents for the induction and remission of IBD. However, prolonged use of anti-inflammatory agents can exert adverse effects on patients. Recently, formulated dietary approach in treating IBD patients is utilized to improve clinical activity scores. An alteration of gastrointestinal microbiota through dietary therapy was found to reduce IBD and is recognized as a promising therapeutic strategy for IBD. One of the recommended formulated diets is an anti-inflammatory diet (AID) that restricts the intake of carbohydrates with modified fatty acids. This diet also contains probiotics and prebiotics that can promote balanced intestinal microbiota composition. However, scientific evidences are limited to support this specific dietary regime in maintaining the remission and prevention relapse of IBD. Therefore, this review aimed to summarize available data from various studies to evaluate the AID diet effectiveness which will be useful for clinicians to manage their IBD patients by application of improved dietary therapy. Korean Association for the Study of Intestinal Diseases 2021-04 2021-02-03 /pmc/articles/PMC8100370/ /pubmed/33525858 http://dx.doi.org/10.5217/ir.2020.00035 Text en © Copyright 2021. Korean Association for the Study of Intestinal Diseases. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Shafiee, Nor Hamizah Manaf, Zahara Abdul Mokhtar, Norfilza M. Raja Ali, Raja Affendi Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title | Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title_full | Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title_fullStr | Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title_full_unstemmed | Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title_short | Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
title_sort | anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100370/ https://www.ncbi.nlm.nih.gov/pubmed/33525858 http://dx.doi.org/10.5217/ir.2020.00035 |
work_keys_str_mv | AT shafieenorhamizah antiinflammatorydietandinflammatoryboweldiseasewhatcliniciansandpatientsshouldknow AT manafzaharaabdul antiinflammatorydietandinflammatoryboweldiseasewhatcliniciansandpatientsshouldknow AT mokhtarnorfilzam antiinflammatorydietandinflammatoryboweldiseasewhatcliniciansandpatientsshouldknow AT rajaalirajaaffendi antiinflammatorydietandinflammatoryboweldiseasewhatcliniciansandpatientsshouldknow |